Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World

被引:61
作者
Burns, Leah [1 ]
Le Roux, Nadege [2 ]
Kalesnik-Orszulak, Robert [5 ]
Christian, Jennifer [3 ]
Hukkelhoven, Mathias [5 ]
Rockhold, Frank [4 ]
O'Donnell, John [1 ]
机构
[1] Bristol Myers Squibb, Worldwide Hlth Econ & Outcomes Res, Princeton, NJ USA
[2] Bristol Myers Squibb, Regulatory Intelligence, Boudry, Switzerland
[3] IQVIA, Durham, NC USA
[4] Duke Clin, Dept Biostat & Bioinformat, Res Inst, Durham, NC USA
[5] Bristol Myers Squibb, Global Regulatory Strategy & Policy, Princeton, NJ USA
关键词
Efficiency; Product effectiveness; Real-world evidence; Regulatory decision making; RECOMMENDATIONS;
D O I
10.1016/j.clinthera.2022.01.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: Interest in leveraging real-world evidence (RWE) to support regulatory decision making for product effectiveness has been increasing globally as evident by the increasing number of regulatory frameworks and guidance documents. However, acceptance of RWE, especially before marketing for regulatory approval, differs across countries. In addition, guidance on the design and conduct of innovative clinical trials, such as randomized controlled registry studies, pragmatic trials, and other hybrid studies, is lacking. Methods: We assessed the global regulatory environment with regard to RWE based on regional availability of the following 3 key regulatory elements: (1) RWE regulatory framework, (2) data quality and standards guidance. and (3) study methods guidance. Findings: This article reviews the available frameworks and existing guidance from across the globe and discusses the observed gaps and opportunities for further development and harmonization. (C) 2022 The Author(s). Published by Elsevier Inc.
引用
收藏
页码:420 / 437
页数:18
相关论文
共 102 条
[1]  
[Anonymous], 2018, Framework for FDAs Real-World Evidence Program
[2]  
[Anonymous], 2013, BEST PRACTICES CONDU
[3]  
[Anonymous], 2019, HMA-EMA joint big data taskforce-summary report Internet
[4]  
[Anonymous], ADAPT SMART
[5]  
[Anonymous], 2016, FIN REP AD PATHW PIL
[6]  
[Anonymous], 2020, ICMRA M COVID 19 REA
[7]  
[Anonymous], E9 Statistical Principles for Clinical Trials
[8]  
[Anonymous], 2016, PUBLIC LAW 114 255 1
[9]  
[Anonymous], 2020, The Diplomat
[10]  
[Anonymous], New Zealand health information | Health Navigator NZ